Sareum announces collaboration with CRT

On June 12, 2004 Sareum Holdings plc (AIM: SAR), the structure-based drug discovery and services business, is pleased to report it has entered into a collaborative agreement with Cancer Research Technology Limited (CRT), the oncology focused technology transfer and development company (Press release, Cancer Research Technology, JUN 12, 2004, View Source [SID1234523442]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, which is on a fee-for-service basis and is for 6 months’ duration, Sareum will provide computational chemistry expertise to support several of CRT’s therapeutic discovery programmes in cancer. Financial terms of the agreement were not disclosed.

Commenting on the announcement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said: "We are delighted that we have been chosen by Cancer Research Technology to provide these drug discovery services and we look forward to making a valuable contribution to their development programmes."

Commenting on the announcement, CRT’s Head of Medicinal Chemistry, Dr Tony Raynham, said: "Importantly, Sareum’s core capabilities in computational chemistry will support CRT’s medicinal chemistry department in the development of drug candidates arising from the research activities of our parent charity Cancer Research UK and our other prestigious international partners."